Inhibition of RNA-binding Proteins with Small Molecules

Overview

Journal Nat Rev Chem

Publisher Springer Nature

Specialty Chemistry

Date 2023 May 2

PMID 37127961

Authors

Peng Wu

Affiliations

Soon will be listed here.

Abstract

Protein-RNA interactions have crucial roles in various cellular activities, which, when dysregulated, can lead to a range of human diseases. The identification of small molecules that target the interaction between RNA-binding proteins (RBPs) and RNA is progressing rapidly and represents a novel strategy for the discovery of chemical probes that facilitate understanding of the cellular functions of RBPs and of therapeutic agents with new mechanisms of action. In this Review, I present a current overview of targeting emerging RBPs using small-molecule inhibitors and recent progress in this burgeoning field. Small-molecule inhibitors that were reported for three representative emerging classes of RBPs, the microRNA-binding protein LIN28, the single-stranded or double-stranded RNA-binding Toll-like receptors and the CRISPR-associated (Cas) proteins, are highlighted from a medicinal-chemistry and chemical-biology perspective. However, although this field is burgeoning, challenges remain in the discovery and characterization of small-molecule inhibitors of RBPs.

Citing Articles

Regulation of gene expression through protein-metabolite interactions.

Hornisch M, Piazza I NPJ Metab Health Dis. 2025; 3(1):7.

PMID: 40052108 PMC: 11879850. DOI: 10.1038/s44324-024-00047-w.

Developing novel Lin28 inhibitors by computer aided drug design.

Matias-Barrios V, Radaeva M, Rosellinny G, Jia Q, Xie N, Villanueva M Cell Death Discov. 2025; 11(1):5.

PMID: 39800739 PMC: 11725581. DOI: 10.1038/s41420-024-02281-z.

Enhanced identification of small molecules binding to hnRNPA1 via cryptic pockets mapping coupled with X-Ray fragment screening.

Dunnett L, Das S, Venditti V, Prischi F bioRxiv. 2025; .

PMID: 39763864 PMC: 11702612. DOI: 10.1101/2024.12.17.628909.

The interplay between epitranscriptomic RNA modifications and neurodegenerative disorders: Mechanistic insights and potential therapeutic strategies.

Hashmi M, Fatima H, Ahmad S, Rehman A, Safdar F Ibrain. 2024; 10(4):395-426.

PMID: 39691424 PMC: 11649393. DOI: 10.1002/ibra.12183.

Endo-bind-n-seq: identifying RNA motifs of RNA binding proteins isolated from endogenous sources.

Hanelt T, Treiber N, Treiber T, Lehmann G, Eichner N, Rothmeier T Life Sci Alliance. 2024; 8(2).

PMID: 39622621 PMC: 11612968. DOI: 10.26508/lsa.202402782.

References

Santos R, Ursu O, Gaulton A, Bento A, Donadi R, Bologa C . A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2016; 16(1):19-34. PMC: 6314433. DOI: 10.1038/nrd.2016.230. View

Clamp M, Fry B, Kamal M, Xie X, Cuff J, Lin M . Distinguishing protein-coding and noncoding genes in the human genome. Proc Natl Acad Sci U S A. 2007; 104(49):19428-33. PMC: 2148306. DOI: 10.1073/pnas.0709013104. View

Hopkins A, Groom C . The druggable genome. Nat Rev Drug Discov. 2002; 1(9):727-30. DOI: 10.1038/nrd892. View

Gerstberger S, Hafner M, Tuschl T . A census of human RNA-binding proteins. Nat Rev Genet. 2014; 15(12):829-45. PMC: 11148870. DOI: 10.1038/nrg3813. View

Plaschka C, Lin P, Nagai K . Structure of a pre-catalytic spliceosome. Nature. 2017; 546(7660):617-621. PMC: 5503131. DOI: 10.1038/nature22799. View

Hentze M, Castello A, Schwarzl T, Preiss T . A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 2018; 19(5):327-341. DOI: 10.1038/nrm.2017.130. View

Lukong K, Chang K, Khandjian E, Richard S . RNA-binding proteins in human genetic disease. Trends Genet. 2008; 24(8):416-25. DOI: 10.1016/j.tig.2008.05.004. View

Conlon E, Manley J . RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev. 2017; 31(15):1509-1528. PMC: 5630017. DOI: 10.1101/gad.304055.117. View

Angelbello A, Chen J, Childs-Disney J, Zhang P, Wang Z, Disney M . Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chem Rev. 2018; 118(4):1599-1663. PMC: 5989578. DOI: 10.1021/acs.chemrev.7b00504. View

10.

Crooke S, Witztum J, Bennett C, Baker B . RNA-Targeted Therapeutics. Cell Metab. 2018; 27(4):714-739. DOI: 10.1016/j.cmet.2018.03.004. View

11.

Kole R, Krainer A, Altman S . RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012; 11(2):125-40. PMC: 4743652. DOI: 10.1038/nrd3625. View

12.

Rinaldi C, Wood M . Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2017; 14(1):9-21. DOI: 10.1038/nrneurol.2017.148. View

13.

Setten R, Rossi J, Han S . The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019; 18(6):421-446. DOI: 10.1038/s41573-019-0017-4. View

14.

Crooke S . Vitravene--another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 1998; 8(4):vii-viii. DOI: 10.1089/oli.1.1998.8.vii. View

15.

Crooke S, Geary R . Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2012; 76(2):269-76. PMC: 3731601. DOI: 10.1111/j.1365-2125.2012.04469.x. View

16.

Scoto M, Finkel R, Mercuri E, Muntoni F . Genetic therapies for inherited neuromuscular disorders. Lancet Child Adolesc Health. 2018; 2(8):600-609. DOI: 10.1016/S2352-4642(18)30140-8. View

17.

Benson M, Waddington-Cruz M, Berk J, Polydefkis M, Dyck P, Wang A . Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018; 379(1):22-31. DOI: 10.1056/NEJMoa1716793. View

18.

Kim J, Hu C, El Achkar C, Black L, Douville J, Larson A . Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med. 2019; 381(17):1644-1652. PMC: 6961983. DOI: 10.1056/NEJMoa1813279. View

19.

Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell D . Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019; 380(6):549-558. DOI: 10.1056/NEJMoa1807838. View

20.

Warner K, Hajdin C, Weeks K . Principles for targeting RNA with drug-like small molecules. Nat Rev Drug Discov. 2018; 17(8):547-558. PMC: 6420209. DOI: 10.1038/nrd.2018.93. View